Brigatinib plus carboplatin–pemetrexed after lorlatinib failure in ALK-rearranged non-small cell lung cancer with co-occurring ALK I1171N and G1269A mutations: a case report
No standard targeted strategy exists after lorlatinib failure in ALK-rearranged non–small cell lung cancer (NSCLC). We report a 41-year-old man with metastatic ALK-rearranged lung adenocarcinoma who progressed sequentially on alectinib and lorlatinib. Re-biopsy with DNA/RNA next-generation sequencing (NGS) at lorlatinib progression revealed an EML4::ALK fusion with co-occurring ALK I1171N and G1269A mutations at high allele fractions, suggesting a cis configuration. Supported by in vitro data, he received brigatinib plus carboplatin–pemetrexed. After four cycles, the primary tumor regressed markedly, nodal disease showed a complete metabolic response, and intracranial findings remained stable. Grade 2 fatigue was the only adverse event; maintenance pemetrexed plus brigatinib is ongoing. Concurrent chemotherapy and short follow-up preclude attributing the response to brigatinib alone. This case highlights the value of repeat biopsy and NGS after lorlatinib failure and suggests that a brigatinib-containing chemotherapy regimen is feasible in this setting.
Authors
- İbrahim Vedat Bayoğlu (ORCID: https://orcid.org/0000-0002-0481-1084)
- Selver Işık (ORCID: https://orcid.org/0000-0002-2726-1740)
- Osman Köstek (ORCID: https://orcid.org/0000-0002-1901-5603)
- Ezgi Çoban (ORCID: https://orcid.org/0000-0003-3309-7972)
- Ali Kaan Güren (ORCID: https://orcid.org/0000-0002-3562-5006)
- Abdüssamet Çelebi (ORCID: https://orcid.org/0000-0002-6922-1018)
- Nazım Can Demircan (ORCID: https://orcid.org/0000-0001-6630-5278)
- Mustafa Alperen Tunç (ORCID: https://orcid.org/0000-0002-1537-3032)
- Murat Sarı (ORCID: https://orcid.org/0000-0003-0596-1559)
- Erkam Kocaaslan (ORCID: https://orcid.org/0000-0002-8994-2904)
- Burak Paçacı (ORCID: https://orcid.org/0000-0002-9543-9053)
- Fırat Akagündüz (ORCID: https://orcid.org/0000-0001-7969-9464)
- Ahmet Demirel (ORCID: https://orcid.org/0000-0001-8162-8294)
- Tugra Hakan Demir (ORCID: https://orcid.org/0009-0007-9564-6355)
Institutions
- Marmara University (TR)
Publication Details
- Journal
- Journal of Chemotherapy
- Published
- 2026-11-16
- DOI
- https://doi.org/10.1080/1120009x.2026.2762664
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 0.00